RecruitingNCT05331066
Understanding immunE-related toXicities by multifACeT Profiling
EXACT - Understanding immunE-related toXicities by multifACeT Profiling
Sponsor
Royal Marsden NHS Foundation Trust
Enrollment
200 participants
Start Date
Apr 6, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
A prospective observational cohort study of patients undergoing CPI therapy in which translational research is the fundamental aspect of the study.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Written informed consent
- Age 18 years or older
- Confirmed diagnosis of any form of solid malignancy with a clinical indication and appropriate treatment plan to commence immune checkpoint inhibitor therapy
Exclusion Criteria4
- Medical or psychological condition that would preclude informed consent
- Planned participation in a drug trial receiving investigational agents
- Subjects who have previously commenced immune checkpoint inhibitor therapy prior to study entry.
- Subjects unable to comply with the study or sample schedule.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05331066
Related Trials
The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease
NCT067958151 location
Implementing AI-Assisted, Patient-Friendly Imaging Report Summaries to Enhance Oncology Care Delivery
NCT075320831 location
Feasibility and Acceptability of Internet-based Parent-child Interaction Therapy (I-PCIT) in Pediatric Cancer
NCT063467821 location
STEP2 vs. Routine Early Palliative Care: Randomized Noninferiority Trial
NCT074466601 location
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
NCT0632641123 locations